SCHEMBL892755

SCHEMBL892755

Nc1ncc(Cl)cc1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL558930 0.76
SCHEMBL10017414 0.76 MAP4K4 (0.58)
SCHEMBL30297014 0.75
SCHEMBL360527 0.75
SCHEMBL30838764 0.75
SCHEMBL23683504 0.75
SCHEMBL120637 0.75
SCHEMBL31556266 0.75
SCHEMBL362099 0.75
SCHEMBL1721286 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087909-A1 COMPOUNDS FOR USE AS NEUROPROTECTIVE AGENTS AND/OR IN INHIBITING FORMATION OF ALPHA-SYNUCLEIN AGGREGATES AC IMMUNE SA (CH) 2026-04-30 WO disclosed
EP-4713093-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH ALPHA-SYNUCLEIN AGGREGATES AC Immune SA (CH) 2026-03-25 EP disclosed
US-20250154145-A1 OXER1 ANTAGONISTS AND USES THEREOF GREEN CHEMISTRY CONSULTING LLC 2025-05-15 US disclosed
US-12208088-B2 Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof GENENTECH, INC. (US) 2025-01-28 US disclosed
WO-2024236059-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH ALPHA-SYNUCLEIN AGGREGATES AC IMMUNE SA (CH) 2024-11-21 WO disclosed
EP-4452940-A1 OXER1 ANTAGONISTS AND USES THEREOF Fairhaven Pharmaceuticals Inc. (CA) 2024-10-30 EP disclosed
EP-3584239-B1 O-AMINOHETEROARYL ALKYNYL-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2024-09-11 EP disclosed
CN-118451061-A OXER1 antagonists and uses thereof 费尔黑文制药公司 2024-08-06 CN disclosed
US-20240132470-A1 Antibacterial Compounds JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2024-04-25 US disclosed
US-11935803-B2 Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-03-19 US disclosed
EP-1636224-A2 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE Prosidion Limited (GB) 2006-03-22 EP disclosed
US-20050261272-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PROSIDION LIMITED (GB) 2005-11-24 US disclosed
WO-2005095400-A1 AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-10-13 WO disclosed
WO-2005095399-A2 NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2005-10-13 WO disclosed
US-20050215582-A1 Substituted pyrrolopyridines ASTRAZENECA AB (SE) 2005-09-29 US disclosed
EP-1539758-A1 SUBSTITUTED PYRROLOPYRIDINES AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004104001-A2 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE PROSIDION LIMITED (GB) 2004-12-02 WO disclosed
WO-2004016610-A1 SUBSTITUTED PYRROLOPYRIDINES ASTRAZENECA AB (SE) 2004-02-26 WO disclosed
US-6476045-B2 INDOLE AND AZAINDOLE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS, AND IN PARTICULAR AS NEUROKININ-1 RECEPTOR ANTAGONIST MERCK SHARP & DOHME LTD. (GB) 2002-11-05 US disclosed
US-20020022624-A1 Azaindole derivatives and their use as therapeutic agents MERCK SHARP & DOHME LTD. (GB) 2002-02-21 US disclosed